A comparative, open label study to evaluate the efficacy and safety of botropase 1cu injection versus tranexamic acid 500mg injection in patients with menorrhagia.

Jagdale industries pvt Ltd0 个研究点目标入组 60 人开始时间: 待定最近更新: 2023年10月16日

试验速览

暂无简介。

•1.Age: 18-49 years
•2.Gender: Female
•3.Agrees to provides a written or electronic copy of the signed informed consent form (ICF)
•4.Diagnosed and admitted with Menorrhagia (admitted at least 1day to define the bleeding scale)
•5.Patients Without any systemic diseases interfering with or influencing coagulation.
•6.Patients with hemogram, bleeding time and clotting time within normal limits and without any bleeding and clotting disorder.
•7.Has an Aadhar ID or equivalent ID proof, smartphone/mobile connectivity and is willing to receive calls and messages connect by health care workers assigned to this project and authorized by this investigator.
•8.Agrees not to self-medicate or take any other therapies during the study and has not been on any such medications other ayurvedic, homoeopathic, Siddha, or other forms of medications for the past 1 (one) week and agrees to not use during the study period.

•1.Individuals not willing to give written consent (wet-ink/electronic)
•2.Known history of allergy or contraindications for Botropase Injection /its components and/or to Tranexamic Acid/ Its components.
•3.Patients with mental illness who cannot comprehend questionnaires.
•4.Patients with conditions that affect blood coagulation- Hemophilia, Hypercoagulability, Thromboembolic predisposition like deranged lipid profile, any bleeding disorder found during screening.
•5.Individuals on any other medications or nutritional supplements that may influence Botropase i.e. any other coagulant or anti-coagulant.
•6.Individuals not willing to follow protocol specified guidelines.
•7.Subjects having any medical or surgical condition that would require immediate medical or surgical intervention at the time of screening for this study or during the course of the study.
•8.History of renal failure or dialysis, hypercalcemia, severe liver disease (cirrhosis), sarcoidosis, or other granulomatous diseases (Wegener)
•9.Previously diagnosed cases of immune-compromised status like HIV, Hepatitis B/C, Tuberculosis, Cancer, etc. or deranged liver or kidney tests
•10.Subjects taking or need to take systemic/oral steroid treatment and or any kind of immunosuppressive therapy in the pre-study and during the study period
•11.Subjects participating in any other clinical study or having participated in any other study

发起方